Diligence memo · auto-generated · as of July 2, 2026
BigHat Biosciences, Inc.
BigHat Biosciences, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
BigHat Biosciences, Inc. operates in Biotechnology, based in SAN MATEO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
BigHat Biosciences, Inc. has raised $148M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $124M on 2022-06-30.
Most recent recorded round closed around 2022-06-30.
Valuation (modeled)modeled
Provath models BigHat Biosciences, Inc. at approximately $2.6B (range $563M–$4.6B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.31× the median modeled value of Series D+ Biotechnology companies in 2022–2024 (75 peers) — value vs value, same stage and era. Within the normal band (131% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 11 months.
Last raise 4.0 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 1.6× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 94% of Biotechnology peers (4293 compared).
Modeled value ranks above 96% of those peers.
Closest niche peers: Areteia Therapeutics, Inc., GIO World Health Ltd, Crinetics Pharmaceuticals, Inc., 2seventy bio, Inc., Gio World Health (Europe) Sa.
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.